Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of single-shot adductor canal block with HR18034 for postoperative analgesia after total knee arthroplasty
CTR20220569Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2022
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liposomal ropivacaine in postoperative pain (6 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Area under the pain intensity-time curve at rest from 0 to 72 hours. Started Oct 2022; status: completed.
02
Drugs
liposomal ropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on CTR20220569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220569.